What should men know about prostate-specific antigen screening before giving informed consent? (Q39479473)

12 September 2017

title

What should men know about prostate-specific antigen screening before giving informed consent? (English)

1 reference

12 September 2017

0 references

Chan EC

1

1 reference

12 September 2017

Sulmasy DP

series ordinal

2

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 October 1998

1 reference

American Journal of Medicine

12 September 2017

published in

1 reference

12 September 2017

volume

105

1 reference

12 September 2017

issue

4

1 reference

12 September 2017

page(s)

266-274

1 reference

Screening for prostate cancer with prostate-specific antigen. An examination of the evidence

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

Prostate Cancer Screening: What We Know and What We Need To Know

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

The mammography and prostate-specific antigen controversies: implications for patient-physician encounters and public policy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

Informed consent for percutaneous lung biopsy: comparison of two consent protocols based on patient recall after the procedure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

The elderly patient and informed consent. Empirical findings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

Strategies to overcome barriers to early detection of cancer among older adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

The importance of patient preference in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

Predictors of interest in prostate-specific antigen screening and the impact of informed consent: what should we tell our patients?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

Informed (but Uneducated) Consent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

Informed Consent for Tests for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

Two models of implementing informed consent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

The use and interpretation of commercial APC gene testing for familial adenomatous polyposis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial of the National Cancer Institute

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0002-9343(98)00257-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(98)00257-5

1 reference

12 September 2017

1 reference